XML 26 R12.htm IDEA: XBRL DOCUMENT
v3.23.1

Restructuring, Impairment, and Related Charges, Net | 12 Months Ended
--- | ---
Mar. 31, 2023
Restructuring and Related Activities [Abstract] |
Restructuring, Impairment, and Related Charges, Net | Restructuring, Impairment, and Related Charges, Net The Company recorded restructuring, impairment, and related charges, net, of $209 million, $281 million, and $334 million in fiscal 2023, fiscal 2022, and fiscal 2021, respectively. These charges are included in “Restructuring, impairment, and related charges, net” in the Consolidated Statements of Operations. Restructuring Initiatives During the fourth quarter of fiscal 2023, the Company approved a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts, with the intent of simplifying its infrastructure and realizing long-term sustainable growth. These initiatives include headcount reductions and the exit or downsizing of certain facilities. The Company anticipates total charges of approximately $125 million across its RxTS and U.S. Pharmaceutical segments as well as Corporate, consisting primarily of employee severance and other employee-related costs, facility and other exit-related costs, as well as long-lived asset impairments. The Company recorded charges of $60 million for the year ended March 31, 2023 related to this program, which reflects severance and other employee-related costs within its RxTS segment as well as asset impairments and accelerated depreciation, including certain asset impairments primarily within its U.S. Pharmaceutical segment and real estate charges within Corporate. This restructuring program is anticipated to be substantially complete by the end of fiscal 2024. During the first quarter of fiscal 2022, the Company approved an initiative to increase operational efficiencies and flexibility by transitioning to a partial remote work model for certain employees. This initiative primarily included the rationalization of the Company’s office space in North America. Where the Company ceased using office space, it exited the portion of the facility no longer used. It also retained and repurposed certain other office locations. The Company recorded charges of $124 million for the year ended March 31, 2022, primarily related to lease right-of-use and other long-lived asset impairments, lease exit costs, and accelerated depreciation and amortization. This initiative was substantially complete in fiscal 2022 after which immaterial charges will continue to be incurred through the termination date of certain leases. During the first quarter of fiscal 2021, the Company committed to an initiative within the U.K., which was included in the Company’s International segment, to further drive operational changes in technologies and business processes, efficiencies, and cost savings. The initiative included reducing the number of retail pharmacy stores, decommissioning obsolete technologies and processes, reorganizing and consolidating certain business operations, and related headcount reductions. Charges incurred for this initiative were not material for the year ended March 31, 2022 and were $57 million for the year ended March 31, 2021, primarily related to asset impairments and accelerated depreciation expense as well as employee severance and other employee-related costs. This initiative was substantially complete in fiscal 2022. During the fourth quarter of fiscal 2019, the Company committed to certain programs to continue its operating model and cost optimization efforts. The Company implemented centralization of certain functions and outsourcing through an expanded arrangement with a third-party vendor to achieve operational efficiency. The programs also included reorganization and consolidation of business operations, related headcount reductions, the further closures of retail pharmacy stores in Europe, and closures of other facilities. The Company recorded charges of $62 million for the year ended March 31, 2021, consisting primarily of employee severance, accelerated depreciation expense, and project consulting fees. This initiative was substantially complete in fiscal 2021. As previously announced on November 30, 2018, the Company relocated its corporate headquarters, effective April 1, 2019, from San Francisco, California to Irving, Texas to improve efficiency, collaboration, and cost competitiveness. As a result, the Company recorded charges of $28 million for the year ended March 31, 2021, consisting primarily of employee retention expenses, severance, long-lived asset impairments, and accelerated depreciation. The relocation was substantially complete in January 2021. Fiscal 2023 Restructuring, impairment, and related charges, net for the year ended March 31, 2023 consisted of the following:
| Year Ended March 31, 2023
(In millions) | U.S. Pharmaceutical (1) |  | Prescription Technology Solutions (1) |  | Medical-Surgical Solutions |  | International |  | Corporate (1) |  | Total
Severance and employee-related costs, net | $ | 6 |  |  | $ | 23 |  |  | $ | 2 |  |  | $ | 4 |  |  | $ | — |  |  | $ | 35 |
Exit and other-related costs (2) | 7 |  |  | 7 |  |  | 3 |  |  | 21 |  |  | 64 |  |  | 102 |
Asset impairments and accelerated depreciation | 25 |  |  | 13 |  |  | 5 |  |  | 10 |  |  | 19 |  |  | 72 |
Total | $ | 38 |  |  | $ | 43 |  |  | $ | 10 |  |  | $ | 35 |  |  | $ | 83 |  |  | $ | 209 |
(1)Includes costs related to operational efficiencies and cost optimization efforts described above to support the Company’s technology solutions. (2)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. Corporate includes costs for business transformation and optimization efforts related to the Company’s technology organization. The International segment includes costs related to the Company’s European divestitures. Fiscal 2022 Restructuring, impairment, and related charges, net for the year ended March 31, 2022 consisted of the following:
| Year Ended March 31, 2022
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Severance and employee-related costs, net | $ | 8 |  |  | $ | 1 |  |  | $ | (1) |  |  | $ | 8 |  |  | $ | (7) |  |  | $ | 9 |
Exit and other-related costs (1) | 9 |  |  | 4 |  |  | 5 |  |  | 33 |  |  | 46 |  |  | 97 |
Asset impairments and accelerated depreciation (2) | 18 |  |  | 20 |  |  | 5 |  |  | 35 |  |  | 61 |  |  | 139 |
Total | $ | 35 |  |  | $ | 25 |  |  | $ | 9 |  |  | $ | 76 |  |  | $ | 100 |  |  | $ | 245 |
(1)Exit and other-related costs consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred. For the Company’s International segment, costs primarily relate to optimization programs in Canada, exit-related actions for the Company’s European Divestiture Activities, and programs for operating model and cost optimization efforts in the U.K. as described above. For Corporate, primarily represents costs related to the transition to the partial remote work model described above and various other initiatives. (2)Costs primarily relate to the transition to the partial remote work model described above. Fiscal 2021 Restructuring, impairment, and related charges, net for the year ended March 31, 2021 consisted of the following:
| Year Ended March 31, 2021
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International (1) |  | Corporate (2) |  | Total
Severance and employee-related costs, net | $ | 10 |  |  | $ | 4 |  |  | $ | (1) |  |  | $ | 22 |  |  | $ | 69 |  |  | $ | 104 |
Exit and other-related costs (3) | 11 |  |  | — |  |  | 4 |  |  | 17 |  |  | 27 |  |  | 59 |
Asset impairments and accelerated depreciation | — |  |  | — |  |  | 1 |  |  | 46 |  |  | 9 |  |  | 56 |
Total | $ | 21 |  |  | $ | 4 |  |  | $ | 4 |  |  | $ | 85 |  |  | $ | 105 |  |  | $ | 219 |
(1)Primarily represents costs associated with the operating model and cost optimization efforts described above. (2)Represents costs associated with the operating model cost optimization efforts and the relocation of the Company’s headquarters described above in addition to various other initiatives. (3)Exit and other-related costs primarily include project consulting fees. The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the years ended March 31, 2023 and 2022:
(In millions) | U.S. Pharmaceutical |  | Prescription Technology Solutions |  | Medical-Surgical Solutions |  | International |  | Corporate |  | Total
Balance, March 31, 2021 | $ | 19 |  |  | $ | 4 |  |  | $ | 3 |  |  | $ | 66 |  |  | $ | 59 |  |  | $ | 151 |
Restructuring, impairment, and related charges, net | 35 |  | 25 |  |  | 9 |  |  | 76 |  |  | 100 |  |  | 245
Non-cash charges | (18) |  |  | (20) |  |  | (5) |  |  | (35) |  |  | (61) |  |  | (139) |
Cash payments | (18) |  |  | (6) |  |  | (6) |  |  | (28) |  |  | (29) |  |  | (87) |
Other (1) | (7) |  |  | — |  |  | — |  |  | (23) |  |  | (10) |  |  | (40) |
Balance, March 31, 2022 (2) | 11 |  |  | 3 |  |  | 1 |  |  | 56 |  |  | 59 |  |  | 130 |
Restructuring, impairment, and related charges, net | 38 |  |  | 43 |  |  | 10 |  |  | 35 |  |  | 83 |  |  | 209 |
Non-cash charges | (25) |  |  | (13) |  |  | (5) |  |  | (10) |  |  | (19) |  |  | (72) |
Cash payments | (9) |  |  | (7) |  |  | (3) |  |  | (10) |  |  | (86) |  |  | (115) |
Other (1) | — |  |  | — |  |  | — |  |  | (58) |  |  | (2) |  |  | (60) |
Balance, March 31, 2023 (3) | $ | 15 |  |  | $ | 26 |  |  | $ | 3 |  |  | $ | 13 |  |  | $ | 35 |  |  | $ | 92 |
(1) Other primarily includes cumulative translation adjustments and transfers to certain other liabilities. For the Company’s International segment, other also includes a reduction to the liability for the divestitures of the E.U. disposal group and the U.K. disposal group in fiscal 2023, as discussed in more detail in Financial Note 2, “Business Acquisitions and Divestitures.” (2) As of March 31, 2022, the total reserve balance was $130 million, of which $58 million was recorded in “Other accrued liabilities,” $36 million was recorded in “Liabilities held for sale,” and $36 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheets. (3) As of March 31, 2023, the total reserve balance was $92 million, of which $66 million was recorded in “Other accrued liabilities” and $26 million was recorded in “Other non-current liabilities” in the Company’s Consolidated Balance Sheets. Long-Lived Asset Impairments Fiscal 2023 There were no material long-lived asset impairments recorded in fiscal 2023. Fiscal 2022 In fiscal 2022, the Company recognized charges totaling $36 million to impair certain long-lived assets within the International segment related to the Company’s previous operations in Denmark and its retail pharmacy businesses in Canada. The Company used an income approach and a market approach to estimate the fair value of the long-lived assets. Fiscal 2021 In fiscal 2021, the Company recognized charges of $115 million to impair certain long-lived assets within the Company’s International segment. These charges primarily related to long-lived assets associated with the Company’s retail pharmacy businesses in Canada and Europe and were due to declines in estimated future cash flows partially driven by a revised outlook regarding the impacts of COVID-19. The Company used both an income approach and a market approach to estimate the fair value of the long-lived assets.

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 5.P.4(e)) -URI https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI https://asc.fasb.org/topic&trid=2175745 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (b)(2) -URI https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration